格隆汇2月6日丨药明康德(603259.SH)在投资者互动平台表示，Chemistry 42属于另一家生物科技公司， 和药明康德无关。公司历来不自行开发新药，也没有用AI来开发新药。 ...

文 | 银行螺丝钉 （转载请注明出处） 今天大盘整体微跌，截止到收盘，还在3.9星。 大盘股下跌。 中证500等中小盘股波动不大。 红利等价值风格略微下跌。 创业板等成长风格盘中上涨，到收盘也变成下跌。 昨天海外市场波动比较大。 美股、商品、虚拟货币大幅波动。 受此影响，今天港股也整体下跌。 港股恒生红利低波动波动小一些，港股科技股下跌。 螺丝钉也汇总了港股指数的估值，供参考，见文章下方图片。 1. 有朋友问，港股红利类指数最近表现比较强，接近历史新高的位置。 但同期港股科技类指数下跌，是因为啥呢？ 其实A股和港股，牛市经常出现成长/价值风格轮动。 港股的指数数量比A股少。 A股价值风格，有红利、低波动、价值、自由现金流等指数。 港股主要是红利类指数，例如恒生红利低波动。 A股成长风格，有A系列龙头策略、有成长、质量等指数，也有创业板科创板。 港股主要是科技类指数，例如港股科技、恒生科技。 2. 2024年9月5.9星以来，港股也出现过几波风格切换。 （1）2024年9月到2025年9月，港股成长风格比较强势。 2025年1-2季度，港股科技股的盈利同比翻倍增长，是最近5年增速最快的时间段。 指数点数=估值* ...

证监会2月6日消息，1月7日，深圳市亚辉龙生物科技股份有限公司披露签署战略合作框架协议的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙立案调 查。 该公告披露后，引发媒体报道及市场关注。经上交所督促，公司于当晚又发布《关于自愿披露签署战略合作框架协议的补充公告》称，脑机星链目前在研 产品的技术路线为非侵入式技术路径，尚无侵入式技术布局，且脑电采集分析仪等产品尚未进入注册申报阶段，有的产品尚处于早期研发阶段或临床前阶 段。 上交所表示，当前，"脑机接口"为市场热点概念，投资者高度关注。特别是，公司股价当日（1月6日）收盘上涨6.52%、成交量较前一个交易日增长 299%，公司披露涉及热点相关信息尤其应当审慎，确保相关信息披露真实、准确、完整，避免对投资者产生误导。公司相关公告对合作方脑机星链技术 路径是否包含侵入式的表述前后不一致，也未就合作协同性、可行性以及后续合作不确定性等投资者关注的重点事项进行充分提示风险，信息披露不准 确、不完整。 公司上述行为违反了《上海证券交易所科创板股票上市规则》相关条款，以及《上海证券交易所科创板上市公司自律监管指引第2号——自愿信息披露》 等有关规定。公司时任董事会秘书王鸣阳作 ...

上交所称，公司上述行为违反了自愿信息披露等相关规则，对亚辉龙及时任董事会秘书王鸣阳予以监管 警示，同时要求公司及董事、高级管理人员采取有效措施对相关违规事项进行整改，结合违规事项，就 公司信息披露及规范运作中存在的合规隐患进行深入排查，制定有针对性的防范措施，切实提高公司信 息披露和规范运作水平。公司需要在收到决定书后的1个月内，向上交所提交经全体董事、高级管理人 员签字确认的整改报告。 2月6日，证监会发布消息，对深圳市亚辉龙生物科技股份有限公司(以下简称"亚辉龙")公告涉嫌误导性 陈述立案调查。 2026年1月7日，亚辉龙披露签署战略合作框架协议的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙 立案调查。下一步，证监会将在全面调查的基础上依法处理，切实维护市场健康发展。 亚辉龙碰瓷"脑机接口" 被上交所监管警示 此前，亚辉龙已经收到上交所监管警示。1月6日收盘后，亚辉龙发布《关于自愿披露签署战略合作框架 协议的公告》公司与深圳脑机星链科技有限公司(以下简称"脑机星链")签订《战略合作框架协议》，双 方将在产品研发、市场推广以及股权投资等方面开展合作，并称脑机星链是一家以人工智能为核心驱动 力，深耕非侵入式与 ...

2026年1月7日，深圳市亚辉龙生物科技股份有限公司（简称亚辉龙）披露签署战 略合作框架协议的公告，涉嫌误导性陈述。近日，我会已对亚辉龙立案调查。下一 步，将在全面调查的基础上依法处理，切实维护市场健康发展。 ...

近日，我会已对亚辉龙立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 据证监会2月6日消息，2026年1月7日，深圳市亚辉龙生物科技股份有限公司(简称亚辉龙)披露签署战略 合作框架协议的公告，涉嫌误导性陈述。 ...

Core Viewpoint - He Yuan Bio (688765.SH), a pre-profit biopharmaceutical company listed on the STAR Market, is facing significant challenges including expanding losses, tight cash flow, uncertainties regarding the commercialization of its core products, and controversies over information disclosure, making it a typical case for observing the survival status of unprofitable STAR Market enterprises [1][7]. Group 1: Continuous Losses and Cash Flow Pressure - He Yuan Bio expects a net profit loss of between 143 million to 167 million yuan for 2025, with cumulative losses exceeding 480 million yuan over the past three years, bringing total losses over four years to over 600 million yuan [2][8]. - The company's main product, recombinant human albumin, accounts for about 80% of revenue, but its selling price has declined from 151.46 yuan per gram in 2022 to 112.69 yuan in the first half of 2025, leading to a continuous decrease in gross margin [2][8]. - The company has incurred over 60 million yuan in litigation-related expenses with Ventria Bioscience, further eroding profits, while cash flow from operating activities has been negative for years, with cash reserves plummeting from 388 million yuan in 2022 to 75 million yuan by September 2025 [2][8]. Group 2: Main Business and Cost Control Challenges - The company attributes its losses to its core product, Aofumin (recombinant human albumin injection), being in the market introduction phase and production ramp-up, yet R&D expenditures have reportedly decreased in 2024 [3][9]. - High professional service fees in management expenses due to litigation reflect challenges in cost control and risk management [3][9]. - The company purchased liability insurance for all directors and executives shortly after its IPO, indicating a self-warning about operational risks despite the relatively small amount of expenditure, raising market scrutiny over its financial discipline [3][9]. Group 3: Core Product Commercialization and Information Disclosure Concerns - The future of He Yuan Bio largely depends on the commercialization prospects of its core product HY1001, but revenue forecasts for 2026 to 2030 have been quietly reduced from 7.255 billion yuan to 5.470 billion yuan, a cut of nearly 1.8 billion yuan, without clear explanation in the prospectus [4][10]. - The product lacks commercial validation, having experienced serious adverse events during Phase I clinical trials, raising concerns about its market readiness [4][10]. - Discrepancies in information disclosure have led to doubts about the rigor and transparency of the company's forecasts, which could continue to affect investor confidence in a market increasingly focused on R&D progress and commercialization capabilities [4][10]. Group 4: Industry Reflection - The case of He Yuan Bio reflects the common predicament faced by many unprofitable STAR Market companies, which must balance expanding losses, tight cash flow, uncertainties in product commercialization, and regulatory compliance in information disclosure [5][11]. - While the STAR Market's fifth set of standards has opened financing avenues for hard tech companies, sustainable business models, robust financial controls, and transparent disclosures remain essential to meet market and investor expectations [5][11]. - For He Yuan Bio, accelerating the commercialization of its core products, improving cash flow, and rebuilding market trust are critical challenges that must be addressed [5][11].

Core Viewpoint - The "15th Five-Year Plan" is expected to provide clear direction and policy support for the capital market, with a focus on traditional industry upgrades, emerging industry demand expansion, and thematic investments in frontier industries [1] Macro Analysis: Opportunities in Financial Assets - The liquidity environment is expected to remain relatively loose both globally and domestically, providing opportunities across various financial assets, with a particular emphasis on the A-share equity market [2] - Current A-share market valuations are considered reasonable based on historical rolling returns, suggesting that the market is not overly expensive [2] - Two core supporting factors for the A-share market include a friendly liquidity environment and an anticipated upward trend in the profit cycle due to improved supply-demand dynamics [2] Trend Assessment: Technological Self-Reliance - The "15th Five-Year Plan" emphasizes technological self-reliance as a strategic task, highlighting the importance of technological innovation and productivity improvement for sustainable economic development [4] Insight into Opportunities: Three Structural Directions - The "15th Five-Year Plan" outlines three key investment directions: 1. Traditional industries such as chemicals, shipbuilding, and metallurgy are expected to enhance profitability through supply-side policies and optimization [5][6] 2. Emerging industries like artificial intelligence and energy storage are projected to experience sustained demand growth, leading to rapid development [6] 3. Frontier industries, including embodied intelligence and quantum technology, are seen as having significant growth potential and should be monitored for breakthroughs in basic scientific research [6] Rational Layout: Understanding Industry Trends - Investors are advised to recognize industry trends and avoid frequent timing based on short-term fluctuations, particularly in the high-growth and high-volatility technology sector [7] - The investment strategy should focus on understanding industry development trends and adjusting strategies only when substantial changes occur in the underlying fundamentals [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 苏州丰倍生物科技股份有限公司（以下简称"公司"）股票于2026年2月4日、2月5日连续2个交易日内 日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。 ● 经公司自查，并向公司控股股东、实际控制人发问询函，截至本公告披露日，除公司已披露的事项 外，不存在其他应披露而未披露的重大信息。 ● 公司股价短期波动幅度较大，敬请广大投资者理性决策，注意投资风险。 一、股票交易异常波动的具体情况 公司股票交易于2026年2月4日、2月5日连续2个交易日内日收盘价格涨幅偏离值累计超过20%，根据 《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，公司目前生产经营活动一切正常，市场环境、行业政策没有发生重大调整、生产成本和销 售等情况没有出现大幅波动、内部生产经营秩序正常。 （二）重大事项情况 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603334 证券简称：丰倍生物 公告编号：2026-001 苏州丰倍生物科技股份有限公司股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 苏州丰倍生物科技股份有限公司（以下简称"公司"）股票于2026年2月4日、2月5日连续2个交易日内 日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。 ● 经公司自查，并向公司控股股东、实际控制人发问询函，截至本公告披露日，除公司已披露的事项 外，不存在其他应披露而未披露的重大信息。 ● 公司股价短期波动幅度较大，敬请广大投资者理性决策，注意投资风险。 一、股票交易异常波动的具体情况 公司股票交易于2026年2月4日、2月5日连续2个交易日内日收盘价格涨幅偏离值累计超过20%，根据 《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，公司目前生产经营活动一切正常 ...